Sifting through countless of stocks in the Pharmaceuticals industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mouth pain under the Chloraseptic brand; eye care products that provide relief from redness and itchiness under the Clear Eyes brand name; at-home removal of common and plantar warts under the Compound W brand; and ear wax removal products under the Debrox brand name. It also provides dental guards, floss picks, interdental brushes, dental repair and kits, and tongue cleaners under the DenTek brand; motion sickness relief products under the Dramamine brand; enemas and other laxative products under the Fleet brand name; stomach upset remedies under the Gaviscon brand; cough drops under the Luden's brand; products for yeast infections in women under the Monistat brand name; lice and parasite treatments under the Nix name; feminine care products, including washes, cloths, and sprays under the Summer's Eve brand; products for dry eyes under the TheraTears brand; nasal saline sprays and washes under the Fess brand name; and oral rehydration products under the Hydralyte brand. It sells its products to mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Latest Pharmaceuticals and Prestige Consumer Healthcare Inc., Pliant Therapeutics, Inc. Stock News

As of September 4, 2026, Prestige Consumer Healthcare Inc. had a $2.5 billion market capitalization, compared to the Pharmaceuticals median of $674.5 million. Prestige Consumer Healthcare Inc.’s stock is down 15.3% in 2026, down 0.4% in the previous five trading days and down 21.71% in the past year.

Currently, Prestige Consumer Healthcare Inc.’s price-earnings ratio is 14.6. Prestige Consumer Healthcare Inc.’s trailing 12-month revenue is $1.1 billion with a 15.6% net profit margin. Year-over-year quarterly sales growth most recently was 6.5%. Analysts expect adjusted earnings to reach $4.568 per share for the current fiscal year. Prestige Consumer Healthcare Inc. does not currently pay a dividend.

As of September 4, 2026, Pliant Therapeutics, Inc. had a $71.8 million market cap, putting it in the 18th percentile of all stocks. Pliant Therapeutics, Inc.’s stock is down 4.9% in 2026, up 4.5% in the previous five trading days and down 28.83% in the past year.

Currently, Pliant Therapeutics, Inc. does not have a price-earnings ratio. Pliant Therapeutics, Inc.’s trailing 12-month revenue is $0.0 million with a % net profit margin. As of September 4, 2026, Pliant Therapeutics, Inc. has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $-1.462 per share for the current fiscal year. Pliant Therapeutics, Inc. does not currently pay a dividend.

How We Compare Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.’s Quality Grades

Company	Ticker	Quality
Prestige Consumer Healthcare Inc.	PBH	C
Pliant Therapeutics, Inc.	PLRX	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Prestige Consumer Healthcare Inc. has a Quality Score of 57, which is Average. Pliant Therapeutics, Inc. has a Quality Score of 41, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. is the better investment when it comes to quality.

Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.’s Momentum Grades

Company	Ticker	Momentum
Prestige Consumer Healthcare Inc.	PBH	D
Pliant Therapeutics, Inc.	PLRX	F

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Prestige Consumer Healthcare Inc. has a Momentum Score of 34, which is Weak. Pliant Therapeutics, Inc. has a Momentum Score of 20, which is Very Weak.

The Momentum Stock Winner: No Clear Winner

Neither Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. has a strong enough Momentum Grade to be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. is the better investment when it comes to momentum.

Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Prestige Consumer Healthcare Inc.	PBH	C
Pliant Therapeutics, Inc.	PLRX	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Prestige Consumer Healthcare Inc. has a Earnings Estimate Score of 42, which is Neutral. Pliant Therapeutics, Inc. has a Earnings Estimate Score of 32, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc. Grades

In addition to Momentum, Estimate Revisions and Quality, A+ Investor also provides grades for Value and Growth.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Prestige Consumer Healthcare Inc., Pliant Therapeutics or Inc. Stock?

Overall, Prestige Consumer Healthcare Inc. stock has a Momentum Score of 34, Estimate Revisions Score of 42 and Quality Score of 57.

Pliant Therapeutics, Inc. stock has a Momentum Score of 20, Estimate Revisions Score of 32 and Quality Score of 41.

Comparing Prestige Consumer Healthcare Inc., Pliant Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.